Ameriprise
TRVI icon

Ameriprise’s Trevi Therapeutics TRVI Stock Holding History

Ameriprise’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.02M Buy
504,836
+180,664
+56% +$2.02M ﹤0.01% 2314
2025
Q4 		$4.06M Buy
+324,172
New +$3.75M ﹤0.01% 2585
2025
Q3 		– Sell
-154,854
Closed -$847K – 4187
2025
Q2 		$847K Buy
154,854
+36,892
+31% +$230K ﹤0.01% 3337
2025
Q1 		$742K Buy
117,962
+21,178
+22% +$101K ﹤0.01% 3336
2024
Q4 		$399K Buy
96,784
+63,067
+187% +$202K ﹤0.01% 3605
2024
Q3 		$113K Buy
33,717
+18,769
+126% +$55.8K ﹤0.01% 3825
2024
Q2 		$44.5K Sell
14,948
-6,660
-31% -$18.5K ﹤0.01% 3821
2024
Q1 		$74.5K Buy
+21,608
New +$48.2K ﹤0.01% 3799

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Ameriprise's TRVI Position: Q1 2026 in Review

Ameriprise increased its Trevi Therapeutics (TRVI) stake by 56% in Q1 2026, buying an estimated $2.02M and bringing the position to 504,836 shares worth $6.02M. The position accounts for ﹤0.01% of the portfolio, ranked #2314.

Ameriprise first reported a position in TRVI in Q1 2024 and has held it in 8 quarters since. 198 funds tracked by Wall St. Rank hold TRVI as of Q1 2026.

  • Ameriprise held 504,836 shares of Trevi Therapeutics worth $6.02M as of Q1 2026.
  • Ameriprise bought 180,664 Trevi Therapeutics shares in Q1 2026, an estimated $2.02M.
  • Trevi Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #2314 holding.
  • Ameriprise first reported a position in Trevi Therapeutics in Q1 2024 and has held it in 8 quarters since.
  • 198 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.